- Home
- CABA vs HUYA Comparison
CABA vs HUYA Comparison
Compare CABA & HUYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CABA | HUYA |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.7M | 572.2M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CABA | HUYA |
|---|---|---|
| Price | $3.25 | $2.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $14.50 | $3.50 |
| AVG Volume (30 Days) | ★ 4.2M | 1.3M |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 81.37% |
| EPS Growth | ★ 10.26 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $14.08 |
| Revenue Next Year | N/A | $6.11 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.44 | $2.08 |
| 52 Week High | $4.23 | $4.93 |
Technical Indicators
Market Signals| Indicator | CABA | HUYA |
|---|---|---|
| Relative Strength Index (RSI) | 58.51 | 29.48 |
| Support Level | $3.12 | $2.08 |
| Resistance Level | $3.34 | $2.55 |
| Average True Range (ATR) | 0.22 | 0.07 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 68.32 | 9.09 |
Price Performance
Historical ComparisonAbout CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
About HUYA HUYA Inc. American depositary shares each representing one ordinary share
Huya officially became independent in 2016 and is headquartered in Guangzhou. It operates a live streaming platform focused on games, esports, and interactive entertainment, and also provides game-related services such as distribution and in-game item sales. Its main livestreaming platforms include Huya Live in China and Nimo TV outside of China. Huya is a subsidiary of Tencent, which owned 67% of its equity stake and held 95% of the voting power, as of the end of 2025.